VolitionRx Limited to Present at Conferences in March 2020.
AUSTIN, Texas, Mar. 3, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that its Executive Vice President, Investor Relations, Scott Powell, is scheduled to present at five conferences in March 2020.
During the conferences, Dr. Powell will outline Volition's business, clinical, regulatory and operational milestones, as well as the Company's recently announced annual results.
Details of the conference presentations are as follows:
Conference: Oppenheimer 30th Annual Healthcare ConferenceDate: Tuesday, March 17, 2020Location: InterContinental New York Barclay Hotel, New York, NY
Conference: BTIG MedTech, Digital Health, Life Science & Diagnostic Tools ConferenceDate: Thursday, March 19, 2020Location: The Cliff Lodge, Snowbird, Utah
Conference: Investor SummitDate: Wednesday, March 25, 2020Location: J.W. Marriott Essex House New York, New York, NY
Conference: Sidoti & Company Spring 2020 Investor ConferenceDate: Thursday, March 26, 2020Location: The Marriott Marquis, New York, NY
Conference: Veyo Partners Emerging Growth Spring InvitationalDate: Thursday, March 26, 2020Location: The Cornell Club, New York, NY
Persons attending any of the above-referenced conferences who would like to schedule a 1-on-1 meeting with Volition management during such conference may do so by contacting Joseph Green of Edison Advisors at JGreen@edisongroup.com or Scott Powell, Executive Vice President of Investor Relations at email@example.com
Additionally, Volition today announced that the Compensation Committee of its Board of Directors has approved the issuance of a warrant to purchase up to 50,000 shares of Volition common stock (the "Warrant") to the Chief Scientific Officer of its wholly-owned subsidiary, Volition America, Inc. ("Volition America"), Ms. Theresa Kelly, as a material inducement to Ms. Kelly's commencing employment with Volition America and in accordance with Section 711 of the NYSE American Company Guide. The Warrant has an exercise price of $3.45 per share and is exercisable commencing September 1, 2021 (subject to continued employment through such date) with an expiration date of March 1, 2026.
For further details please contact firstname.lastname@example.org.
Volition is a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life. The tests are based on the science of NucleosomicsTM, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. Volition is primarily focused on human diagnostics but also has a subsidiary focused on animal diagnostics.
Volition's research and development activities are centered in Belgium, with additional offices in Texas, London and Singapore, as the company focuses on bringing its diagnostic products to market.
NucleosomicsTM is a trademark and/or service mark of VolitionRx Limited and its subsidiaries.
For more information about Volition, visit Volition's website volition.com or connect with us via:
Twitter: https://twitter.com/volitionrx LinkedIn: https://www.linkedin.com/company/volitionrx Facebook: https://www.facebook.com/VolitionRx/ YouTube: https://www.youtube.com/user/VolitionRx
The contents found at Volition's website address, Twitter, LinkedIn, Facebook, and YouTube are not incorporated by reference into this document and should not be considered part of this document. The addresses for Volition's website, Twitter, LinkedIn, Facebook, and YouTube are included in this document as inactive textual references only.
Media / Investor Contacts
Louise Batchelor, Volition
+44 (0)7557 774620
Scott Powell, Volition
+1 (646) 650 1351
Joseph Green, Edison Advisors
+1 (646) 653 7030
View original content:http://www.prnewswire.com/news-releases/volitionrx-limited-to-present-at-conferences-in-march-2020-301015276.html
SOURCE VolitionRx Ltd